Bora Lim

44PUBLICATIONS
380CO-AUTHORS
Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Sep 06, 2026
Trastuzumab Deruxtecan-Associated Pneumonitis in Non-Breast Solid Tumors: A Retrospective Cohort Study.

|Aug 21, 2026
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.

|Jul 16, 2026
Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.

|Jul 15, 2026
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

|May 13, 2026
Ecotypes of triple-negative breast cancer in response to chemotherapy.

|Oct 21, 2025
A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease).

Bora Lim, Angela Marx, Megumi Kai

Pageof 8

Frequent Collaborators

12 joint publications

Naoto Ueno

9 joint publications

Debu Tripathy

5 joint publications

Jonathan T Lei

5 joint publications

Jason White